Skip to main content
SpringerLink
Log in

Notfälle unter medikamentöser Tumortherapie

Emergencies under drug anti-cancer treatment

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Onkologische Notfälle sind in der Ätiologie und Symptomatik vielfältig und treten häufig mit der Einleitung einer Chemotherapie auf, können sich aber auch während oder mit zeitlicher Verzögerung manifestieren. Die Kenntnis onkologischer Notfälle unter medikamentöser Tumortherapie ist daher nicht nur für die behandelnden Fachdisziplinen wichtig, sondern auch für mit- oder weiterbetreuende Kollegen. Jeder dieser Krankheitszustände erfordert eine sorgfältige Beurteilung der Symptome, klinische, laborchemische und apparative diagnostische Schritte sowie akute Interventionen und unterstützende Pflegemaßnahmen. Im Folgenden werden sechs häufige, akut verlaufende und/oder schwerwiegende Nebenwirkungen vorgestellt und auf das spezifische Management eingegangen.

Abstract

Oncological emergencies are manifold in the etiology and symptoms and often occur with the initiation of chemotherapy but can also present during treatment or after a delay in time. Knowledge of oncological emergencies under drug treatment for cancer is crucial not only for hematologists and medical oncologists but also for other personnel involved in primary care and multidisciplinary treatment concepts. Each of these illness situations necessitates careful evaluation of the symptoms, clinical, laboratory and further diagnostic steps as well as acute interventions and supportive care measures. In this article six frequent, acutely occurring and/or severe side effects are presented and the specific management is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Alter P, Herzum M, Soufi M et al (2006) Cardiotoxicity of 5‑fluorouracil. Cardiovasc Hematol Agents Med Chem 4:1–5

    Article  CAS  Google Scholar 

  2. Arriola E, Wheater M, Karydis I et al (2015) Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 21:5642–5643

    Article  Google Scholar 

  3. Berman D, Parker SM, Siegel J et al (2010) Blockade of cytotoxic T‑lymphocyte antigen‑4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10:11

    PubMed  PubMed Central  Google Scholar 

  4. Biffi R, Pozzi S, Agazzi A et al (2004) Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 15:296–300

    Article  CAS  Google Scholar 

  5. Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11

    Article  Google Scholar 

  6. Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220

    Article  CAS  Google Scholar 

  7. Cassagnol M, Mcbride A (2009) Management of chemotherapy extravasations. US Pharm 34(9):3–11

    Google Scholar 

  8. Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:559–574

    Article  CAS  Google Scholar 

  9. Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778

    Article  CAS  Google Scholar 

  10. Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213

    Article  CAS  Google Scholar 

  11. De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801

    Article  Google Scholar 

  12. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) Supportive Therapie bei onkologischen PatientInnen – Langversion 1.1, 2017, AWMF Registernummer: 032/054OL. http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html. Zugegriffen: 12. Sept. 2019

    Google Scholar 

  13. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346–1353

    Article  Google Scholar 

  14. Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5:309–316

    Article  Google Scholar 

  15. Gupta A, De Felice KM, Loftus EV Jr. et al (2015) Systematic review: colitis associated with anti-CTLA‑4 therapy. Aliment Pharmacol Ther 42:406–417

    Article  CAS  Google Scholar 

  16. Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142

    Article  CAS  Google Scholar 

  17. Heinzerling L, Ott PA, Hodi FS et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4:50

    Article  Google Scholar 

  18. Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854

    Article  CAS  Google Scholar 

  19. Howard SC, Trifilio S, Gregory TK et al (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95:563–573

    Article  CAS  Google Scholar 

  20. Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5‑fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493

    Article  CAS  Google Scholar 

  21. Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671

    Article  Google Scholar 

  22. Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert Opin Drug Saf 5:791–809

    Article  CAS  Google Scholar 

  23. Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095

    Article  Google Scholar 

  24. Langer SW, Sehested M, Jensen PB (2009) Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori 95:273–282

    Article  CAS  Google Scholar 

  25. Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609

    Article  CAS  Google Scholar 

  26. Ma WW, Saif MW, El-Rayes BF et al (2017) Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5‑fluorouracil and capecitabine toxicity. Cancer 123:345–356

    Article  CAS  Google Scholar 

  27. Marthey L, Mateus C, Mussini C et al (2016) Cancer immunotherapy with anti-CTLA‑4 Monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10:395–401

    Article  CAS  Google Scholar 

  28. Mercuro G, Cadeddu C, Piras A et al (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12:1124–1133

    Article  CAS  Google Scholar 

  29. Miller KK, Gorcey L, Mclellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787–794

    Article  Google Scholar 

  30. Mouridsen HT, Langer SW, Buter J et al (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546–550

    Article  CAS  Google Scholar 

  31. Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD‑1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391

    Article  CAS  Google Scholar 

  32. Perez Fidalgo JA, Garcia Fabregat L, Cervantes A et al (2012) Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol 23(Suppl 7):vii167–vii173

    Article  Google Scholar 

  33. Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol 71:203.e1–203.12 (quiz 215–206)

    Article  CAS  Google Scholar 

  34. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

    Article  CAS  Google Scholar 

  35. Rosen AC, Balagula Y, Raisch DW et al (2014) Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 25:225–234

    Article  CAS  Google Scholar 

  36. Sara JD, Kaur J, Khodadadi R et al (2018) 5‑fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. https://doi.org/10.1177/1758835918780140

    Article  PubMed  PubMed Central  Google Scholar 

  37. Schimmel KJ, Richel DJ, Van Den Brink RB et al (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191

    Article  CAS  Google Scholar 

  38. Sudhoff T, Enderle MD, Pahlke M et al (2004) 5‑Fluorouracil induces arterial vasocontractions. Ann Oncol 15:661–664

    Article  CAS  Google Scholar 

  39. Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728

    Article  Google Scholar 

  40. Wengstrom Y, Margulies A (2008) European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs 12:357–361

    Article  CAS  Google Scholar 

  41. Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD‑1 therapy. Eur J Cancer 60:210–225

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, LMU München, Marchioninistraße 15, 81377, München, Deutschland

    Annabel Alig,  Michael von Bergwelt &  Clemens Gießen-Jung

Authors
  1. Annabel Alig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael von Bergwelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Gießen-Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Gießen-Jung.

Ethics declarations

Interessenkonflikt

A. Alig, M. von Bergwelt und C. Gießen-Jung geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alig, A., von Bergwelt, M. & Gießen-Jung, C. Notfälle unter medikamentöser Tumortherapie. Onkologe 26, 120–128 (2020). https://doi.org/10.1007/s00761-019-00672-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-019-00672-x

Schlüsselwörter

Keywords

Search

Navigation